A new guidance on individual patient expanded access requests for investigational COVID-19 treatments appears to reflect US Food and Drug Administration commissioner Stephen Hahn’s view that some agency processes and policies adopted during the novel coronavirus outbreak should outlast the public health emergency.
Released on 2 June, the guidance provides recommendations on key factors and procedures that institutional review boards should consider...







